CLAIMS:

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt~~, prodrug or bioisostere~~ thereof, wherein:

R^{1a}, R^{1b}, R^{1c}, and R^{1d} are each independently selected from the group consisting of H, halogen, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy, and CN;

X^1 is C_{1-3} alkylene, optionally substituted with one or two C_{1-2} alkyl or CO_2H;

R^{2a} and R^{2b} are each independently selected from the group consisting of H, C_{1-8} alkyl, C_{1-8} haloalkyl, -Y, -X^2-$C(O)_2R^a$, -X^2-OR^a, -X^2-NR^aR^b, -X^2-$CONR^aR^b$, -X^2-SO_2R^a, -X^2-$SO_2NR^aR^b$, -X^2-SO_3R^a, and –X^2-Y, wherein each X^2 is C_{1-6} alkylene, and any C_{1-8} alkyl or C_{1-6} alkylene, is optionally further substituted with one or two members independently selected from OH, SO_2NH_2, $CONH_2$, C(O)NHOH, PO_3H_2, COO-C_{1-8} alkyl, ~~or~~ and CO_2H, and each Y is selected from the group consisting of C_{3-6} cycloalkyl, C_{4-8} heterocyclyl, and 5- to 6-membered heteroaryl, each of which is optionally further substituted with one to four substituents independently selected from the group consisting of oxo, OH, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{1-4} hydroxyalkoxy, SO_2NH_2, $CONH_2$, C(O)NHOH, PO_3H_2, COO-C_{1-8} alkyl, SO_3H, and CO_2H;

or R^{2a} and R^{2b} are combined to form a 4- to 10-membered ring or spirocyclic ring, optionally having one or two additional ring vertices selected from O, N, and ~~or~~ S;

wherein the 4- to 10-membered ring or spirocyclic ring formed by combining R^{2a} and R^{2b}, is substituted with 0 to 4 substituents independently selected from the group consisting of oxo, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, -X^3-$C(O)_2R^a$, -X^3-OR^a, -X^3-NR^aR^b, -X^3-$CONR^aR^b$, -X^3-SO_2R^a,

$-X^3-SO_2NR^aR^b$,

and $-X^3-SO_3R^a$; wherein X^3 is a bond or C_{1-6} alkylene;

R^3 and R^4 are each independently selected from the group consisting of F, Cl, CN, CH_3, OCH_3, CH_2CH_3, and CF_3;

the subscript n is 0, 1, 2, or 3;

each R^{3a} is independently selected from the group consisting of H, F, Cl, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{2-3} alkenyl, and CN;

R^6, R^7, and R^8 are each independently selected from the group consisting of H, F, Cl, CN, CH_3, OCH_3, CH_2CH_3, and CF_3;

A is a member selected from the group consisting of $-N(R^a)-$, $-C(=O)N(R^a)-$, $-S(O)N(R^a)-$, and $-S(O)_2N(R^a)-$;

Z is selected from the group consisting of:

i) a monocyclic, bicyclic, or spirocyclic non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with up to four R^a and/or R^b;

ii) a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three R^c; and

iii) a fused bicyclic heteroaryl ring, optionally substituted with one to three R^c;

wherein when A is $-N(R^a)-$, then Z is a fused bicyclic heteroaryl ring optionally substituted with one to three R^c;

each R^a is independently selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkylene-CO_2H, and C_{1-6} alkylene-SO_3H;

each R^b is independently selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkylene-CO_2H, and C_{1-6} alkylene-SO_3H, each of which is optionally further substituted with one or two members independently selected from OH, SO_2NH_2, $CONH_2$, C(O)NHOH, PO_3H_2, COO-C_{1-8} alkyl, and CO_2H;

and R^a and R^b, when attached to the same nitrogen atom, are optionally combined to form a 4- to 8-membered ring or spirocyclic ring, optionally substituted with halogen, OH, SO_2NH_2, $CONH_2$, C(O)NHOH, PO_3H_2, COO-C_{1-8} alkyl, or CO_2H;

each R^c is independently selected from the group consisting of H, halogen, CN, C_{1-6} alkyl, C_{1-6} haloalkyl, $-Y^1$, $-X^4-C(O)_2R^a$, $-O-X^4-C(O)_2R^a$, $-X^4-OR^a$, $-X^4-NR^aR^b$, $-X^4-CONR^aR^b$,

-O-X^4-CONR^{a}R^b, -X^4-SO$_2$R^a, -X^4-SO$_2$NR^{a}R^b, -X^4-SO$_3$R^a, and -N(R^a)-X^4-C(O)$_2$R^a, wherein each X^4 is a bond or C_{1-6} alkylene, and each Y^1 is selected from the group consisting of C_{3-6} cycloalkyl and C_{4-8} heterocyclyl; and

optionally two R^c on adjacent ring vertices are combined to form a fused 5- or 6-membered heterocyclic ring.

2. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, having formula (Ia):



(Ia).

3. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, having formula (Ib):



(Ib).

4. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, having formula (Ic):



(Ic).

5. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, having formula (Id):



(Id).

6. The compound of any one of claims **1** to **5,** or a pharmaceutically acceptable salt thereof, wherein the group R^{1a} is OCH_3 and R^{1b} is F.

7. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)-, and Z is selected from the group consisting of:

i) a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with up to four R^a and/or R^b; and

ii) a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three R^c.

8. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein Z is a non-aromatic heterocyclic ring having a formula selected from the group consisting of:



.

9. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three R^c; and said ~~heterocyclic~~ heteroaryl ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, and pyrazolyl.

10. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein Z is a non-aromatic heterocyclic ring selected from the group consisting of piperidinyl, morpholinyl, tetrahydropyranyl, and tetrahydrofuranyl, each of which is optionally substituted with up to four R^a and/or R^b.

11. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein A is $–N(R^a)-$, and Z is a fused bicyclic heteroaryl ring, optionally substituted with one to three R^c.

12. The compound of claim **1** or **11**, or a pharmaceutically acceptable salt thereof, wherein Z is a fused bicyclic heteroaryl ring having a formula selected from the group consisting of:



and

.

13. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein R^{2a} and R^{2b} are each H.

14. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein R^{2a} and R^{2b} are combined to form a 4- to 9-membered ring or spirocyclic ring, optionally having one or two additional ring vertices selected from O, N, ~~or~~ and S; wherein said ring or spirocyclic ring is substituted with 0 to 4 substituents independently selected from the group consisting of oxo, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, -~~X^2~~X^3-$C(O)_2R^a$,

-~~X^2~~X^3-OR^a, -~~X^2~~X^3-NR^{a}R^b, -~~X^2~~X^3-CONR^{a}R^b, -~~X^2~~X^3-SO$_2$R^a, -~~X^2~~X^3-SO$_2$NR^{a}R^b, and –~~X^2~~X^3-SO$_3$R^a; wherein ~~X^2~~-X^3 is a bond or C$_{1-6}$ alkylene.

15. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein –N(R^{2a})(R^{2b}) is selected from the group consisting of:



.

16. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein –N(R^{2a})(R^{2b}) is selected from the group consisting of:



.

17. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein $-N(R^{2a})(R^{2b})$ is selected from the group consisting of:



.

18. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein R^{2a} is H or C_{1-8} alkyl; and R^{2b} is –Y or $–X^2$-Y.

19. The compound of any one of claims **1** to **18**, or a pharmaceutically acceptable salt thereof, wherein the compound is an optically pure or enriched isomer.

20. The compound of claim **18**, or a pharmaceutically acceptable salt thereof, wherein Y is selected from the group consisting of C_{3-6} cycloalkyl and C_{4-8} heterocyclyl, each of which is optionally further substituted with one to four substituents independently selected from the group consisting of oxo, OH, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{1-4} hydroxyalkoxy, SO_2NH_2, $CONH_2$, C(O)NHOH, PO_3H_2, COO-C_{1-8}alkyl, SO_3H, and CO_2H.

21. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)- and Z is a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with R^a and/or R^b.

22. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)- and Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three R^c.

23. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)-; Z is a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with R^a and/or R^b; and each of R^{1c}, R^6, R^7, and R^8 is H.

24. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)-; Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three R^c; and each of R^{1c}, R^6, R^7, and R^8 is H.

25. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)-; Z is a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with R^a and/or R^b; and said non-aromatic heterocyclic ring is selected from the group consisting of piperidinyl, morpholinyl, tetrahydropyranyl, and tetrahydrofuranyl.

26. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)-; Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three R^c; and said ~~heterocyclic~~ heteroaryl ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, and pyrazolyl.

27. The compound of claim **1**, which is selected from:

Cmpd. No.	Structure
1.001	
1.002	

Cmpd. No.	Structure
1.003	
1.004	
1.005	
1.006	
1.007	
1.008	
1.009	
1.010	

Cmpd. No.	Structure
1.011	
1.012	
1.013	
1.014	
1.015	
1.016	
1.017	

Cmpd. No.	Structure
1.018	
1.019	
1.020	
1.021	
1.022	
1.023	
1.024	
1.025	

Cmpd. No.	Structure
1.026	
1.027	
1.028	
1.029	
1.030	
1.031	
1.032	
1.033	

Cmpd. No.	Structure
1.034	
1.035	
1.036	
1.037	
1.038	
1.039	
1.040	
1.041	

Cmpd. No.	Structure
1.042	
1.043	
1.044	
1.045	
1.046	
1.047	
1.048	
1.049	

Cmpd. No.	Structure
1.050	
1.051	
1.052	
1.053	
1.054	
1.055	
1.056	

Cmpd. No.	Structure
1.057	
1.058	
1.059	
1.060	
1.061	
1.062	
1.063	
1.064	

Cmpd. No.	Structure
1.065	
1.066	
1.067	
1.068	
1.069	
1.070	
1.071	

Cmpd. No.	Structure
1.072	
1.073	
1.074	
1.075	
1.076	
1.077	
1.078	

Cmpd. No.	Structure
1.079	
1.080	
1.081	
1.082	
1.083	
1.084	
1.085	
1.086	

Cmpd. No.	Structure
1.087	
1.088	
1.089	
1.090	
1.091	
1.092	
1.093	
1.094	

Cmpd. No.	Structure
1.095	
1.096	
1.097	
1.098	
1.099	
1.100	
1.101	
1.102	

Cmpd. No.	Structure
1.103	
1.104	
1.105	
1.106	
1.107	
1.108	
1.109	
1.110	

Cmpd. No.	Structure
1.111	
1.112	
1.113	
1.114	
1.115	
1.116	
1.117	
1.118	

Cmpd. No.	Structure
1.119	
1.120	
1.121	
1.122	
1.123	
1.124	
1.125	

Cmpd. No.	Structure
1.126	
1.127	
1.128	
1.129	
1.130	
1.131	
1.132	

Cmpd. No.	Structure
1.133	
1.134	
1.135	
1.136	
1.137	
1.138	
1.139	

Cmpd. No.	Structure
1.140	
1.141	
1.142	
1.143	
1.144	
1.145	
1.146	

Cmpd. No.	Structure
1.147	
1.148	
1.149	
1.150	
1.151	
1.152	
1.153	

Cmpd. No.	Structure
1.154	
1.155	
1.156	
1.157	
1.158	
1.159	
1.160	

Cmpd. No.	Structure
1.161	
1.162	
1.163	
1.164	
1.165	
1.166	
1.167	

Cmpd. No.	Structure
1.168	
1.169	
1.170	
1.171	
1.172	
1.173	
1.174	

Cmpd. No.	Structure
1.175	
1.176	
1.177	
1.178	
1.179	
1.180	
1.181	

Cmpd. No.	Structure
1.182	
1.183	
1.184	
1.185	
1.186	
1.187	
1.188	

Cmpd. No.	Structure
1.189	
1.190	
1.191	
1.192	
1.193	
1.194	
1.195	

Cmpd. No.	Structure
1.196	
1.197	
1.198	
1.199	
1.200	
1.201	
1.202	

Cmpd. No.	Structure
1.203	
1.204	
1.205	
1.206	
1.207	
1.208	
1.209	

Cmpd. No.	Structure
1.210	
1.211	
1.212	
1.213	
1.214	
1.215	
1.216	
1.217	

Cmpd. No.	Structure
1.218	
1.219	
1.220	
1.221	
1.222	
1.223	
1.224	

Cmpd. No.	Structure
1.225	
1.226	
1.227	
1.228	
1.229	
1.230	
1.231	

Cmpd. No.	Structure
1.232	
1.233	
1.234	
1.235	
1.236	
1.237	
1.238	
1.239	

Cmpd. No.	Structure
1.240	
1.241	
1.242	
1.243	
1.244	
1.245	
1.246	
1.247	

Cmpd. No.	Structure
1.248	
1.249	
1.250	
1.251	
1.252	
1.253	
1.254	
1.255	

Cmpd. No.	Structure
1.256	
1.257	
1.258	
1.259	
1.260	
1.261	
1.262	
1.263	

Cmpd. No.	Structure
1.264	
1.265	
1.266	
1.267	
1.268	
1.269	
1.270	
1.271	

Cmpd. No.	Structure
1.272	
1.273	
1.274	
1.275	
1.276	
1.277	
1.278	

Cmpd. No.	Structure
1.279	
1.280	
1.281	
1.282	
1.283	
1.284	
1.285	

Cmpd. No.	Structure
1.286	
1.287	
1.288	
1.289	
1.290	
1.291	

Cmpd. No.	Structure
1.292	
1.293	
1.294	
1.295	
1.296	
1.297	
1.298	

Cmpd. No.	Structure
1.299	
1.300	
1.301	
1.302	
1.303	
1.304	
1.305	

Cmpd. No.	Structure
1.306	
1.307	
1.308	
1.309	
1.310	
1.311	
1.312	
1.313	

Cmpd. No.	Structure
1.314	
1.315	
1.316	
1.317	
1.318	
1.319	
1.320	
1.321	

Cmpd. No.	Structure
1.322	
1.323	
1.324	
1.325	
1.326	
1.327	
1.328	
1.329	

Cmpd. No.	Structure
1.330	
1.331	
1.332	
1.333	
1.334	
1.335	
1.336	
1.337	

Cmpd. No.	Structure
1.338	
1.339	
1.340	
1.341	
1.342	
1.343	
1.344	
1.345	

Cmpd. No.	Structure
1.346	
1.347	
1.348	
1.349	
1.350	
1.351	
1.352	
1.353	

Cmpd. No.	Structure
1.354	
1.355	
1.356	
1.357	
1.358	
1.359	
1.360	
1.361	
1.362	

Cmpd. No.	Structure
1.363	
1.364	
1.365	
1.366	
1.367	
1.368	
1.369	
1.370	

Cmpd. No.	Structure
1.371	
1.372	
1.373	
1.374	
1.375	
1.376	
1.377	

Cmpd. No.	Structure
1.378	
1.379	
1.380	
1.381	
1.382	
1.383	
1.384	

Cmpd. No.	Structure
1.385	
1.386	
1.387	
1.388	
1.389	
1.390	
1.391	
1.392	

Cmpd. No.	Structure
1.393	
1.394	
1.395	
1.396	
1.397	
1.398	
1.399	
1.400	
1.401	

Cmpd. No.	Structure
1.402	

or a pharmaceutically acceptable salt thereof.

28. The compound of claim **1**, which is selected from

Cmpd. No.	Structure
2.001	
2.002	
2.003	
2.004	
2.005	

Cmpd. No.	Structure
2.006	
2.007	
2.008	
2.009	
2.010	
2.011	
2.012	

Cmpd. No.	Structure
2.013	
2.014	
2.015	
2.016	
2.017	
2.018	
2.019	

Cmpd. No.	Structure
2.020	
2.021	
2.022	
2.023	
2.024	
2.025	
2.026	

Cmpd. No.	Structure
2.027	
2.028	
2.029	
2.030	
2.031	
2.032	
2.033	

Cmpd. No.	Structure
2.034	
2.035	
2.036	
2.037	
2.038	
2.039	
2.040	

Cmpd. No.	Structure
2.041	
2.042	
2.043	
2.044	
2.045	
2.046	
2.047	

Cmpd. No.	Structure
2.048	
2.049	
2.050	
2.051	
2.052	
2.053	
2.054	

Cmpd. No.	Structure
2.055	
2.056	
2.057	
2.058	
2.059	
2.060	
2.061	

Cmpd. No.	Structure
2.062	
2.063	
2.064	
2.065	
2.066	
2.067	
2.068	

Cmpd. No.	Structure
2.069	
2.070	
2.071	
2.072	
2.073	
2.074	
2.075	

Cmpd. No.	Structure
2.076	
2.077	
2.078	
2.079	
2.080	
2.081	
2.082	

Cmpd. No.	Structure
2.083	
2.084	
2.085	
2.086	
2.087	
2.088	
2.089	

Cmpd. No.	Structure
2.090	
2.091	
2.092	
2.093	
2.094	
2.095	
2.096	

Cmpd. No.	Structure
2.097	
2.098	
2.099	
2.100	
2.101	
2.102	
2.103	

Cmpd. No.	Structure
2.104	
2.105	
2.106	
2.107	
2.108	
2.109	
2.110	

Cmpd. No.	Structure
2.111	
2.112	
2.113	
2.114	
2.115	

or a pharmaceutically acceptable salt thereof.

29. The compound of claim **1**, which is



, or a pharmaceutically acceptable salt thereof.

30. The compound of claim **1**, which is



,

or a pharmaceutically acceptable salt thereof.

31. The compound of claim **1**, which is



,

or a pharmaceutically acceptable salt thereof.

32. The compound of claim **1**, which is



,

or a pharmaceutically acceptable salt thereof.

~~27~~**33.** A pharmaceutical composition comprising a compound of any one of claims **1** to ~~26~~**32**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

~~**28.** Use of a compound of any one of claims **1** to **26**, or a pharmaceutically acceptable salt thereof or a composition of claim **27** in the preparation of a medicament for modulating an immune response mediated by the PD-1 signaling pathway in a subject.~~

~~29~~**34.** Use of a compound of any one of claims **1** to ~~26~~**32**, or a pharmaceutically acceptable salt thereof, or a composition of claim ~~27~~ **33** in the preparation of a medicament for

treating a subject suffering from or susceptible to an infectious disease, a bacterial infectious disease, a viral infectious disease, a fungal infectious disease, a solid tumor, a hematological malignancy, an immune disorder, an inflammatory disease, and cancer~~a disease or disorder mediated by the PD-1 signaling pathway~~.

~~**30.** The use of any one of claims **28** to **29**, wherein the subject suffers from a disease or disorder selected from the group consisting of an infectious disease, a bacterial infectious disease, a viral infectious disease a fungal infectious disease, a solid tumor, a hematological malignancy, an immune disorder, an inflammatory disease, and cancer.~~

~~31~~**35.** Use of a compound of any one of claims **1** to **32**, or a pharmaceutically acceptable salt thereof, or a composition of claim **33** in the preparation of a medicament for treating a subject suffering from or susceptible to a ~~The use of claim **29**, wherein the~~ disease or disorder ~~is~~ selected from the group consisting of melanoma, glioblastoma, esophagus tumor, nasopharyngeal carcinoma, uveal melanoma, lymphoma, lymphocytic lymphoma, primary CNS lymphoma, T-cell lymphoma, diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, prostate cancer, castration-resistant prostate cancer, chronic myelocytic leukemia, Kaposi's sarcoma fibrosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, angiosarcoma, lymphangiosarcoma, synovioma, ~~,~~ meningioma, leiomyosarcoma, rhabdomyosarcoma, sarcoma of soft tissue, sarcoma, sepsis, biliary tumor, basal cell carcinoma, thymus neoplasm, cancer of the thyroid gland, cancer of the parathyroid gland, uterine cancer, cancer of the adrenal gland, liver infection, Merkel cell carcinoma, nerve tumor, follicle center lymphoma, colon cancer, Hodgkin's disease, non-Hodgkin's lymphoma, leukemia, chronic or acute leukemias, ~~including~~ acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, ovary tumor, myelodysplastic syndrome, cutaneous or intraocular malignant melanoma, renal cell carcinoma, small-cell lung cancer, lung cancer, mesothelioma, breast cancer, squamous non-small cell lung cancer ~~(SCLC)~~, non-squamous non-small cell lung cancer~~NSCLC~~, colorectal cancer, ovarian cancer, gastric cancer, hepatocellular carcinoma, pancreatic carcinoma, pancreatic cancer, ~~Pancreatic~~ pancreatic ductal adenocarcinoma, squamous cell carcinoma of the head and neck, cancer of the head or neck, gastrointestinal tract, stomach cancer, ~~,~~HIV, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, herpes viruses, papillomaviruses, influenza, bone cancer, skin cancer,

rectal cancer, cancer of the anal region, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the urethra, cancer of the penis, cancer of the bladder, cancer of the kidney, cancer of the ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, epidermoid cancer, abestosis, carcinoma, adenocarcinoma, papillary carcinoma, cystadenocarcinoma, bronchogenic carcinoma, renal cell carcinoma, transitional cell carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, ~~wilm's~~ Wilms tumor, pleomorphic adenoma, liver cell papilloma, renal tubular adenoma, cystadenoma, papilloma, adenoma, leiomyoma, rhabdomyoma, hemangioma, lymphangioma, osteoma, chondroma, lipoma, and fibroma.